• 1
    Fisher B,Costantino JP,Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 13711388.
  • 2
    Vogel VG,Costantino JP,Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295: 27272741.
  • 3
    Ma H,Bernstein L,Pike MC,Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies [serial online]. Breast Cancer Res. 2006; 8: R43.
  • 4
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet. 2002; 360: 187195.
  • 5
    World Health Organization. Global Strategy for Infant and Young Child Feeding. Geneva, Switzerland: World Health Organization; 2003.
  • 6
    Thune I,Furberg AS. Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med Sci Sports Exerc. 2001; 33( 6 suppl): S530S550; discussion S609–S610.
  • 7
    McTiernan A,Kooperberg C,White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA. 2003; 290: 1331136.
  • 8
    IARC Working Group on the Evaluation of Cancer-Preventive Agents:Weight Control and Physical Activity: IARC Handbooks of Cancer Prevention, Volume 6. Lyon, France: IARC Press; 2002.
  • 9
    Campbell KL,McTiernan A. Exercise and biomarkers for cancer prevention studies. J Nutr. 2007; 137( 1 suppl): 161S169S.
  • 10
    McTiernan A. Mechanisms linking physical activity with cancer. Nature Reviews Cancer. 2008; 8: 205211.
  • 11
    [No authors listed] Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894: ixii, 1–253.
  • 12
    WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363: 157163.
  • 13
    Morimoto LM,White E,Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control. 2002; 13: 741751.
  • 14
    Huang Z,Hankinson SE,Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997; 278: 14071411.
  • 15
    World Cancer Research Fund Panel (Potter J, Chair). Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 1997.
  • 16
    Smith-Warner SA,Spiegelman D,Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA. 2001; 285: 769776.
  • 17
    Greenwald P. Cancer prevention clinical trials. J Clin Oncol. 2002; 20( 18 suppl): 14S22S.
  • 18
    Singletary KW,Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA. 2001; 286: 21432151.
  • 19
    Hamajima N,Hirose K,Tajima K, et al. Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002; 87: 12341245.
  • 20
    Cogliano V,Grosse Y,Baan R,Straif K,Secretan B,El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005; 6: 552553.
  • 21
    [No authors listed] Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1996; 347: 17131727.
  • 22
    Vessey M,Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer. 2006; 95: 385389.
  • 23
    Haile RW,Thomas DC,McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev. 2006; 15: 18631870.
  • 24
    [No authors listed] Breast cancer and hormone replacement therapy,: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997; 350: 10471059.
  • 25
    Chlebowski RT,Hendrix SL,Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003; 289: 32433253.
  • 26
    Stefanick ML,Anderson GL,Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006; 295: 16471657.
  • 27
    McTiernan A,Martin CF,Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst. 2005; 97: 13661376.
  • 28
    Porter P. “Westernizing” women's risks? Breast cancer in lower-income countries. N Engl J Med. 2008; 358: 213216.